The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction

Objectives. To investigate the add-on effect of solifenacin for Japanese men with remaining overactive bladder (OAB) symptoms after tamsulosin monotherapy for lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) in real-life clinical practice. Methods. Patients aged...

Full description

Saved in:
Bibliographic Details
Main Authors: Naoya Masumori, Taiji Tsukamoto, Masahiro Yanase, Hiroki Horita, Masaharu Aoki
Format: Article
Language:English
Published: Wiley 2010-01-01
Series:Advances in Urology
Online Access:http://dx.doi.org/10.1155/2010/205251
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849686060064309248
author Naoya Masumori
Taiji Tsukamoto
Masahiro Yanase
Hiroki Horita
Masaharu Aoki
author_facet Naoya Masumori
Taiji Tsukamoto
Masahiro Yanase
Hiroki Horita
Masaharu Aoki
author_sort Naoya Masumori
collection DOAJ
description Objectives. To investigate the add-on effect of solifenacin for Japanese men with remaining overactive bladder (OAB) symptoms after tamsulosin monotherapy for lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) in real-life clinical practice. Methods. Patients aged ≥ 50 having remaining OAB symptoms (≥ 3 of OAB symptom score (OABSS) with ≥2 of urgency score) after at least 4 weeks treatment by 0.2 mg of tamsulosin for BPO/LUTS received 2.5 or 5.0 mg of solifenacin for 12 weeks. The International Prostate Symptom Score (IPSS), QOL index and OABSS, maximum flow rate (Qmax) and postvoid residual urine volume (PVR) were determined. Results. A total of 48 patients (mean age 72.5 years) completed the study. There were significant improvement in IPSS (15.1 to 11.2) and QOL index (4.2 to 3.0) by add-on of solifenacin. Although the IPSS storage symptom score was significantly improved, there were no changes observed in the IPSS voiding symptom score. The OABSS showed significant improvement (8.0 to 4.8). No changes were observed in Qmax and PVR. Conclusions. Under the supervision of an experienced urologist, the additional administration of solifenacin to patients with BPO/LUTS treated with tamsulosin, is effective in controlling remaining OAB symptoms.
format Article
id doaj-art-ba9d24e8efaa474e932a0aaf5ffb52e2
institution DOAJ
issn 1687-6369
1687-6377
language English
publishDate 2010-01-01
publisher Wiley
record_format Article
series Advances in Urology
spelling doaj-art-ba9d24e8efaa474e932a0aaf5ffb52e22025-08-20T03:22:52ZengWileyAdvances in Urology1687-63691687-63772010-01-01201010.1155/2010/205251205251The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic ObstructionNaoya Masumori0Taiji Tsukamoto1Masahiro Yanase2Hiroki Horita3Masaharu Aoki4Department of Urology, Sapporo Medical University School of Medicine, 060-8543 Sapporo, JapanDepartment of Urology, Sapporo Medical University School of Medicine, 060-8543 Sapporo, JapanDepartment of Urology, Sunagawa City Hospital, 073-0196 Sunagawa, JapanDepartment of Urology, Saiseikai Otaru Hospital, 047-0044 Otaru, JapanDepartment of Urology, Kushiro Red Cross Hospital, 085-8512 Kushiro, JapanObjectives. To investigate the add-on effect of solifenacin for Japanese men with remaining overactive bladder (OAB) symptoms after tamsulosin monotherapy for lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) in real-life clinical practice. Methods. Patients aged ≥ 50 having remaining OAB symptoms (≥ 3 of OAB symptom score (OABSS) with ≥2 of urgency score) after at least 4 weeks treatment by 0.2 mg of tamsulosin for BPO/LUTS received 2.5 or 5.0 mg of solifenacin for 12 weeks. The International Prostate Symptom Score (IPSS), QOL index and OABSS, maximum flow rate (Qmax) and postvoid residual urine volume (PVR) were determined. Results. A total of 48 patients (mean age 72.5 years) completed the study. There were significant improvement in IPSS (15.1 to 11.2) and QOL index (4.2 to 3.0) by add-on of solifenacin. Although the IPSS storage symptom score was significantly improved, there were no changes observed in the IPSS voiding symptom score. The OABSS showed significant improvement (8.0 to 4.8). No changes were observed in Qmax and PVR. Conclusions. Under the supervision of an experienced urologist, the additional administration of solifenacin to patients with BPO/LUTS treated with tamsulosin, is effective in controlling remaining OAB symptoms.http://dx.doi.org/10.1155/2010/205251
spellingShingle Naoya Masumori
Taiji Tsukamoto
Masahiro Yanase
Hiroki Horita
Masaharu Aoki
The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
Advances in Urology
title The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
title_full The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
title_fullStr The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
title_full_unstemmed The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
title_short The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
title_sort add on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction
url http://dx.doi.org/10.1155/2010/205251
work_keys_str_mv AT naoyamasumori theaddoneffectofsolifenacinforpatientswithremainingoveractivebladderaftertreatmentwithtamsulosinforlowerurinarytractsymptomssuggestiveofbenignprostaticobstruction
AT taijitsukamoto theaddoneffectofsolifenacinforpatientswithremainingoveractivebladderaftertreatmentwithtamsulosinforlowerurinarytractsymptomssuggestiveofbenignprostaticobstruction
AT masahiroyanase theaddoneffectofsolifenacinforpatientswithremainingoveractivebladderaftertreatmentwithtamsulosinforlowerurinarytractsymptomssuggestiveofbenignprostaticobstruction
AT hirokihorita theaddoneffectofsolifenacinforpatientswithremainingoveractivebladderaftertreatmentwithtamsulosinforlowerurinarytractsymptomssuggestiveofbenignprostaticobstruction
AT masaharuaoki theaddoneffectofsolifenacinforpatientswithremainingoveractivebladderaftertreatmentwithtamsulosinforlowerurinarytractsymptomssuggestiveofbenignprostaticobstruction
AT naoyamasumori addoneffectofsolifenacinforpatientswithremainingoveractivebladderaftertreatmentwithtamsulosinforlowerurinarytractsymptomssuggestiveofbenignprostaticobstruction
AT taijitsukamoto addoneffectofsolifenacinforpatientswithremainingoveractivebladderaftertreatmentwithtamsulosinforlowerurinarytractsymptomssuggestiveofbenignprostaticobstruction
AT masahiroyanase addoneffectofsolifenacinforpatientswithremainingoveractivebladderaftertreatmentwithtamsulosinforlowerurinarytractsymptomssuggestiveofbenignprostaticobstruction
AT hirokihorita addoneffectofsolifenacinforpatientswithremainingoveractivebladderaftertreatmentwithtamsulosinforlowerurinarytractsymptomssuggestiveofbenignprostaticobstruction
AT masaharuaoki addoneffectofsolifenacinforpatientswithremainingoveractivebladderaftertreatmentwithtamsulosinforlowerurinarytractsymptomssuggestiveofbenignprostaticobstruction